Happy New Year! Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:
Abbvie is developing a cocktail of drugs to treat people with cystic fibrosis, which if proven effective and safe — and eventually approved — might grab a meaningful slice of Vertex Pharma’s $7 billion-plus cystic fibrosis treatment franchise. The probability that this scenario plays out in Abbvie’s favor — or doesn’t — will become clearer once readouts from two mid-stage clinical trials are announced early in the quarter.
Create a display name to comment
This name will appear with your comment